Literature DB >> 16464518

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.

Amber R Engel1, Pedro F C Vasconcelos, Monica A McArthur, Alan D T Barrett.   

Abstract

Although the live attenuated yellow fever (YF) 17D vaccine is considered to be one of the safest vaccines in the world today, several cases of disease associated with administration of the vaccine have been reported, including YF vaccine-associated viscerotropic disease (YF-VAVD), which was first described in 1996. All YF-VAVD isolates sequenced to date have shown very little genomic change when compared to their parental vaccine strains. In this study, we report the characterization of an isolate, BeH291597 (Brazil75), from a 1975 fatal case of YF-VAVD in Brazil. Comparison of Brazil75 with the genomic sequence of the parental 17DD vaccine strain revealed two amino acid substitutions (at positions M-49 and NS4B-240) that were unique to Brazil75. Although still a rare occurrence, this isolate suggests that YF-VAVD has been present much longer than previously recognized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464518     DOI: 10.1016/j.vaccine.2006.01.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

2.  NIAID workshop on Flavivirus immunity.

Authors:  Alison D Augustine; M Cristina Cassetti; Francis A Ennis; Eva Harris; William H Hildebrand; Patricia M Repik
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

3.  Vaccinating in disease-free regions: a vaccine model with application to yellow fever.

Authors:  Claudia T Codeço; Paula M Luz; Flavio Coelho; Alison P Galvani; Claudio Struchiner
Journal:  J R Soc Interface       Date:  2007-12-22       Impact factor: 4.118

4.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

5.  Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Authors:  Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

6.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

7.  Yellow fever virus vaccine-associated deaths in young women.

Authors:  Stephen J Seligman
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

Review 8.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

Review 9.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

10.  Gamma-interferon exerts a critical early restriction on replication and dissemination of yellow fever virus vaccine strain 17D-204.

Authors:  Kate D Ryman; L K Metthew Lam; Alan M Watson; William B Klimstra
Journal:  NPJ Vaccines       Date:  2018-01-23       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.